tiprankstipranks
Advertisement
Advertisement
PMV Pharmaceuticals price target lowered to $4 from $16 at Evercore ISI
PremiumThe FlyPMV Pharmaceuticals price target lowered to $4 from $16 at Evercore ISI
2M ago
PMV Pharmaceuticals Advances Rezatapopt Interaction Study, Signaling Steady Progress in TP53-Driven Oncology
Premium
Company Announcements
PMV Pharmaceuticals Advances Rezatapopt Interaction Study, Signaling Steady Progress in TP53-Driven Oncology
3M ago
PMV Pharmaceuticals reports FY25 EPS ($1.48), consensus ($1.51)
Premium
The Fly
PMV Pharmaceuticals reports FY25 EPS ($1.48), consensus ($1.51)
3M ago
Promising Developments in PMV Pharmaceuticals’ PYNNACLE Phase 2 Trial Boost Buy Rating
PremiumRatingsPromising Developments in PMV Pharmaceuticals’ PYNNACLE Phase 2 Trial Boost Buy Rating
7M ago
Buy Rating Affirmed for PMV Pharmaceuticals Amid Stable Financials and Strategic Growth Potential
Premium
Ratings
Buy Rating Affirmed for PMV Pharmaceuticals Amid Stable Financials and Strategic Growth Potential
7M ago
PMV Pharmaceuticals reports Q3 EPS (40c), consensus (40c)
Premium
The Fly
PMV Pharmaceuticals reports Q3 EPS (40c), consensus (40c)
7M ago
PMV Pharmaceuticals Reports Promising Phase 2 Trial Results
PremiumCompany AnnouncementsPMV Pharmaceuticals Reports Promising Phase 2 Trial Results
9M ago
PMV Pharmaceuticals announces interim data from Phase 2 portion of PYNNACLE
Premium
The Fly
PMV Pharmaceuticals announces interim data from Phase 2 portion of PYNNACLE
9M ago
PMV Pharmaceuticals Reports Q2 2025 Financial Results
Premium
Company Announcements
PMV Pharmaceuticals Reports Q2 2025 Financial Results
10M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100